JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer
© Desai et al.; licensee BioMed Central Ltd. 2012
Received: 20 August 2011
Accepted: 23 May 2012
Published: 23 May 2012
We developed an analytic strategy that correlates gene expression and clinical outcomes as a means to identify novel candidate oncogenes operative in breast cancer. This analysis, followed by functional characterization, resulted in the identification of Jumonji Domain Containing 6 (JMJD6) protein as a novel driver of oncogenic properties in breast cancer.
Through microarray informatics, Cox proportional hazards regression was used to analyze the correlation between gene expression and distant metastasis-free survival (DMFS) of patients in 14 independent breast cancer cohorts. JMJD6 emerged as a top candidate gene robustly associated with poor patient survival. Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.
JMJD6 was expressed at highest levels in tumors associated with worse outcomes, including ER- and basal-like, Claudin-low, Her2-enriched, and ER+ Luminal B tumors. High nuclear JMJD6 protein was associated with ER negativity, advanced grade, and poor differentiation in tissue microarrays. Separation of ER+/LN- patients that received endocrine monotherapy indicated that JMJD6 is predictive of poor outcome in treatment-specific subgroups. In breast cancer cell lines, loss of JMJD6 consistently resulted in suppressed proliferation but not apoptosis, whereas forced stable overexpression increased growth. In addition, knockdown of JMJD6 in invasive cell lines, such as MDA-MB231, decreased motility and invasion, whereas overexpression in MCF-7 cells slightly promoted motility but did not confer invasive growth. Microarray analysis showed that the most significant transcriptional changes occurred in cell-proliferation genes and genes of the TGF-β tumor-suppressor pathway. High proliferation was characterized by constitutively high cyclin E protein levels. The inverse relation of JMJD6 expression with TGF-β 2 could be extrapolated to the breast cancer cohorts, suggesting that JMJD6 may affect similar pathways in primary breast cancer.
JMJD6 is a novel biomarker of tumor aggressiveness with functional implications in breast cancer growth and migration.
In breast cancer, resistance to standard-of-care systemic adjuvant treatments such as endocrine and chemotherapies remains a major health burden and prompts the need for novel therapeutic targets for patients with advanced, unresponsive, or relapsed disease. We previously used gene-expression profiles of breast tumors to identify extracellular/secretory proteins and cell surface-receptor genes whose high expression levels associate with poor clinical end points. For example, we recently identified serine protease inhibitor Kazal-type 1 (SPINK1) as an important therapeutic target in breast cancer by using a combined genotype and phenotype screening approach. We found that inhibition of SPINK1 by neutralizing antibodies curtailed multiple aggressive properties, including cell survival, invasiveness, and chemoresistance . A second candidate identified in the same study was the phosphatidylserine receptor (PTDSR).
Formerly, PTDSR was thought to be a cell-surface protein that facilitates recruitment of phagocytic cells to sites of apoptosis. Antibodies against PTDSR and annexin V have been used in combination to estimate apoptosis . Mouse knockouts of PTDSR showed early postnatal lethality and had growth retardation and multiple developmental abnormalities due to insufficient differentiation during embryogenesis; however, no defect in apoptotic clearance of cells was evident . By generation of deletion mutants and immune localization, Cui et al.  demonstrated that PTDSR is a nuclear protein, with five nuclear localization signals scattered throughout its sequence. Later, PTDSR was renamed Jumonji domain containing 6 (JMJD6) based on the presence of its JMJC domain with bifunctional histone arginine demethylation and lysyl oxidase activity [4–6]. JMJD6 is homologous to the hypoxia-inducible factor (HIF) asparaginyl-hydroxylase, suggesting a function in cellular response to hypoxia. In addition, JMJD6 protein was recently shown to interact with splicing factor U2AF65; however, very few splicing events in a limited number of genes were attributable to JMJD6 expression . In endothelial cells, alternate splicing of VEGF receptor (Flt1) by U2AF65 promoted endothelial cell migration, and siRNA-mediated knockdown of JMJD6 in endothelial cells led to decreased migration . Based on X-ray crystallographic data, it was predicted and shown that apart from its enzymatic activity, JMJD6 protein bound single-stranded RNA . These diverse findings predict a range of versatile functions for JMJD6, at the transcriptional, splicing, posttranscriptional, and biochemical levels. However, very little is known about the role of JMJD6 in cancer and the molecular pathways that may impinge on disease initiation and prognosis.
Because our in silico analysis demonstrated a robust positive association between JMJD6 expression and breast cancer recurrence, we investigated its phenotypic and molecular effects in breast cancer cells. We report herein that perturbation of JMJD6 expression modulates cell proliferation and cell scattering and motility: phenotypes associated with cancer metastasis. Furthermore, our findings suggest that these cellular phenotypes may be elicited by JMJD6-mediated suppression of transforming growth factor-beta 2 (TGF-β2) and/or activation of proteins that potentiate cell division in a cell type-specific manner. These in vitro mechanistic findings are consistent with the clinical observations that JMJD6 expression correlates positively with proliferation index and high histologic grade but inversely with TGF-β2 expression. Together, these data implicate JMJD6 function in breast tumor progression and suggest a diagnostic role for JMJD6 in predicting patient outcomes.
Materials and methods
Breast cancer clinical datasets
Tumor-expression profiles were obtained with approval from and in accordance with the policies of the institutional review boards of the respective institutions. An integrated "Super Cohort" (SC) of 15 individual Affymetrix array datasets comprising 2,116 breast cancer patients was used in this analysis. These datasets were previously described in detail in Soon et al. . These cohorts were accessible from public databases, Gene Expression Omnibus (National Center for Biotechnology Information, Bethesda, MD, USA), ArrayExpress (European Bioinformatics Institute, Hinxton, UK), and caArray (National Cancer Institute, NIH, Atlanta, GA, USA). Appropriate permission has been granted for the use of the datasets and corresponding de-identified clinical data. A summary of the clinical dataset details and literature references can be found in Additional file 1, Table S1. Initial discovery and meta-analysis was performed on a subset of this Super Cohort.
All raw data (CEL files) were preprocessed and normalized by using the R software package , and library files provided via the Bioconductor . Raw data were MAS5.0 normalized on a per-cohort basis by using the justMAS function in the simpleaffy library from Bioconductor (no background correction, target intensity of 600). Cross-cohort batch effects were corrected by using the COMBAT empirical Bayes method . Normalized JMJD6 probesets, 212722_s_at and 212723_at, were averaged for the analysis of data from Affymetrix U133 arrays, and JMJD6 probe, AB011157, was used for the analysis of the Agilent array dataset (that is, the NKI dataset). Of 2,116 array profiles in the Super Cohort, 1,954 patient cases are annotated with distant metastasis-free survival (DMFS) time and event information.
Clinical survival analysis and expression in subtypes
Distant metastasis-free survival (DMFS) was used as the clinical end point of interest. A DMFS event was defined as metastatic recurrence to a distant organ site or in a limited number of cases, as death owing to progressive breast cancer. Cox proportional hazard regression analysis of JMJD6 expression with DMFS data (Time and Event) was performed in individual patient datasets and in the Super Cohort. Clinical subtype analysis was performed by using the Super Cohort. Intrinsic subtypes were assigned via the PAM50 algorithm of Parker et al. , by using the code provided by the authors at UNC Microarray Database . Gene data were matched by symbol and median centered, and Spearman correlation was used to assign samples to the nearest PAM50 centroid. Claudin-Low subtypes were assigned based on the method described by Prat et al. , by using the microarray data (GSE18229) and information provided by the authors at UNC Microarray Database . Claudin-Low and Normal centroids were generated, and samples were assigned to one or the other class based on euclidean distance to the class centroid. The PAM50 and Claudin-Low subtype information was then combined with the PAM50 subtype used, unless a sample had been classified as Claudin-Low, in which case, the Claudin-Low assignment would take precedence.
Distribution of JMJD6 expression in various breast cancer subtypes was analyzed with the Kruskal-Wallis one-way analysis of variance (ANOVA) on ranks and multiple pairwise comparisons with the Dunn method by using Sigma Plot. Statistical significance of differential JMJD6 expression in ER-positive versus ER-negative tumors was analyzed by using the Mann-Whitney Rank Sum Test. In Kaplan-Meier and CoxPH survival analysis of JMJD6 expression cohorts in the clinical subtypes, the patients were separated by median expression across the Super Cohort into high and low JMJD6-expression groups. Kaplan-Meier survival analysis also was performed on patient groups ranked by quartile expression within each clinical subtype. All survival analyses were performed by using Sigma Plot .
Tissue microarray (TMA) blocks containing cores from 98 breast cancer patients were constructed, as described previously, under institutional ethics committee approval with consent for the tissue microarray program (NUS-IRB 05-017) [1, 16, 17] and used for the analysis. Anti-JMJD6 monoclonal antibody (Santa Cruz, Santa Cruz, CA, USA: Sc-28348) was used at a dilution of 1:50 along with antigen retrieval by heat and Tris-EDTA (pH 9.1). Automated IHC scoring was performed with the Ariol SL-50 image analysis system (Applied Imaging, Santa Clara, CA, USA). Positivity of JMJD6 nuclear expression was defined as nuclear-staining intensity and percentage coverage scores ≥25%. Odds-ratio analysis was performed on JMJD6-positive expression and clinicopathologic features of the tumors by using PASW Statistics 18 .
All cell lines were obtained from American Type Culture Collection (ATCC) and maintained in growth media, at 37°C with 5% CO2. The growth medium for MCF-7, CAMA-1, and BT-549 was Dulbecco Modified Eagle Medium (DMEM), with 10% fetal bovine serum (FBS); and for MDA-MB231 and T47D, it was RPMI-1640, with 10% FBS.
Cloning and expression of JMJD6
JMJD6 (NM_001081461.1) (J1) was amplified by using MCF-7 mRNA (forward primer: 5'CCCAAGCTTATGAACCACAAGAGCAAGAAG3'; reverse primer: 5' GCTCTAGATCACCTGGAGGAGCTGCG 3'), followed by reamplification with forward primer: 5' GAGGTACCATGAACCACAAGAGCA 3' and reverse primer: 5' CGCTCGAGTGGGGGTGAGCCCGGCCT 3' and ligated into TOPO pCR2.1 vector. All clones were sequence verified. JMJD6 was cloned from TOPO vectors into a gateway entry vector pENTR3C (Invitrogen) and then recombined into the lentivirus vector pLenti6.2/V5-DEST (Invitrogen), pLenti4/V5-Dest (Invitrogen), and pcDNA3.1/V5-Dest (Invitrogen) by LR recombination, according to the manufacturer's protocol. For lentiviral clones, pLenti6.2/V5-DEST or pLenti4/V5-Dest was co-transfected with packaging vectors (Invitrogen) into 293 FT cells, and the supernatant was harvested approximately 48 hours for packaged lentivirus. For infection of MCF-7 cells, the cells were plated at 50% confluence and incubated with 20 μl to 30 μl of the concentrated virus and 8 μg/ml of hexamethrine bromide (Polybrene) for 24 hours at 37°C. The cells were replated and cultured with Zeocin (Invitrogen) to obtain several clones (MCF7-J1-OE). The pcDNA3.1 vector was used to generate JMJD6 expression clones by transfection by using Lipofectamine 2000 (Invitrogen) into MDA-MB231, T47D, and CAMA cell lines. Stable clones were selected with gentamycin (Gibco).
Knockdown of JMJD6 gene
SiRNA was reverse transfected (by using manufacturer's protocol) by using Lipofectamine 2000 (Invitrogen) into the cell lines. At 48 hours after transfection, the cells were reconstituted in fresh media for experimental assays. JMJD6 siRNAs used were as follows: siRNA A (Ambion: 111915)- gcuauggugaacacccuaatt; siRNA B (Dharmacon: D-010363-01)- gaacugggauucacaucga; siRNA C (Dharmacon: D-010363-02)- ggauaacgauggcuacuca; and siRNA D (Dharmacon: D- 010363-05)- ggacccggcacaacuacua. A nontargeting scrambled siRNA served as a negative control (Ambion: 4635).
For proliferation assay, cells were plated in 96-well plates at a density of 5,000 cells per well. Cell proliferation was measured by using WST-1 (Roche) every 24 hours over a 4- to 5-consecutive-day period, according to manufacturer's protocol. For detecting apoptosis, cells were transfected in a 96-well plate with siRNAs and assessed for apoptotic markers after 48 hours. In brief, the cells were fixed with paraformaldehyde, and cells were permeabilized with Triton-X 100. Fixed cells were probed with active PARP (BD, 552596) antibody, and the primary antibodies were detected by a secondary antibody conjugated to fluors Alexa 488 (BD, A21121). ArrayScan VTI (Cellomics) was used to detect immunofluorescence, and the baseline threshold was set by using cells stained with secondary antibody alone in the absence of the primary antibody.
Cells were plated in six-well plates at a density of 300 cells per well and grown in DMEM with 10% FBS. Fifteen fields of colonies per cell type were captured on day 7 of growth and blindly scored for three categories of scattering (compact, loose, and scatter) by two random individuals from six people. An average score was calculated for each colony, and the percentage of colonies for each category of scattering was plotted .
Cells were plated in culture inserts (Ibidi) with approximately 500 μM gap. After 2 days (confluent cells), the inserts were removed, and fresh medium with 5 μg/ml of mitomycin C (Calbiochem, 47589) was added. The distances moved by the cells across the gap were measured at 24 hours and calculated as a ratio over the initial distance at 0 hours, and these data were further normalized to the ratio of distance in Vec control.
Invasion and migration assay
In vitro migration and invasion of the cells were assessed by using Falcon FluoroBlok 24-Multiwell inserts with 8-μm pores (BD Biosciences). For invasion assays, the inserts were coated with 20 μg of Matrigel in 80 μl of serum-free media. Cell suspension (200 μl) in serum-free media was loaded into each transwell insert, and 750 μl of medium with 10% FBS was provided in the lower chamber; 4 × 104 MDA-MB231/BT-549 cells were loaded in each transwell. The assay was done for 18 hours for migration and 24 hours for invasion. The cells that had migrated or invaded through the inserts were fixed with 3.7% formaldehyde and stained with propidium iodide, 2 μg/ml (Calbiochem), for 30 minutes, washed with PBS, and counted for 10 fields by using the Target Activation Bioapplication on an ArrayScan VTI (Cellomics). Assay results for siRNA-treated MDA-MB231 cells were normalized to fold change observed in proliferation at Day 2 and then calculated as a ratio to the Sc siRNA control.
Microarray data analysis
MCF-7 J1 clones were harvested for RNA isolation at 80% confluence. For siRNA-mediated knockdown of JMJD6 in MCF-7 and MDA-MB231, the cells were harvested for RNA isolation immediately, 48 hours after transfection. Cells were washed twice with PBS and harvested by trypsinization. RNA was extracted by Trizol (Invitrogen) according to manufacturer's protocol. Three biological replicates of MCF-7 J1 clones and two independent siRNA-transfection replicates were used for the microarray hybridization. Processing of samples for hybridization on Affymetrix U133 Plus 2.0 was done according to manufacturer's protocol. The microarray data were uploaded to Gene Expression Omnibus (accession number, GSE31782). Raw data were MAS5-normalized and log transformed by using Genespring GX11.5. To extract differential gene expression, GeneSpring GX 11.5 was used to perform two-way ANOVA for siRNA-specific changes in MCF-7 and MDA-MB231. The list of significantly differential genes (P < 0.05) was further filtered for genes with at least 1.5-fold change in expression in at least one of the siRNA treatments for either MCF-7 or MDA-MB231. For MCF-7 J1-OE clones, one-way ANOVA was performed to extract differential gene expression in the overexpression clones as compared with the Vec. Only genes that differed in their expression by 1.5-fold in at least one of the clones were selected for further analysis. Genes that overlapped in both siRNA treatment and in J1 clones and those that were regulated in the opposite direction were selected for Ingenuity Pathway Analysis (IPA) . Hierarchical clustering by average linkage and visualization of the clusters was performed by using Cluster and Treeview, respectively [21, 22].
To extract differential gene expression specific to MDA-MB231, GeneSpring GX11.5 was used to perform one-way ANOVA in MDA-MB231 and MCF-7 independently. The list of significant genes that were differentially expressed (1.5-fold; P < 0.05) was filtered. Probesets unique to MDA-MB231 that were absent in MCF-7 lists were extracted for IPA functional analysis.
Total RNA was reverse transcribed by using Maxima reverse transcriptase mix (Fermentas). Real-time PCR was performed by using SYBR-Green PCR Mix (Fermentas) and run on CFX384 Real Time PCR Detection System (Biorad). Ct values were generated by using CFX manager software (Biorad). The primers used are listed in the Additional file 2, Table S2.
To obtain conditioned media, plated cells were incubated with serum-free media for 24 hours before collection. The media were spun down to remove any cell debris and then concentrated ×60 to 80 by using Amicon Ultra centrifugation filter (Millipore).
Whole-cell lysates were prepared by using RIPA buffer for all antibodies, except TGF-βs, detected in conditioned media. Protein concentration was quantified by using Protein Assay reagent (Biorad) with BSA standards. Equal amounts of total protein lysates (20 to 40 μg) were analyzed on an SDS-PAGE gel and transferred to PVDF membrane (GE Healthcare and Millipore). Antibodies against JMJD6 (Abcam, ab10526), β-actin (Sigma, A5441), V5 tag (Invitrogen, R960-25), E-cadherin (Cell Signaling, 4065), vimentin (BD Pharmingen, 550513), TGF-β2 (Abcam, ab36495), phosphorylated SMAD2 (Cell Signaling, 3108 and 3104), phosphorylated SMAD3 (Cell Signaling, 4520), SMAD2/3 (Cell Signaling, 3102), cyclin D1 (ab24249), cyclin E1 (Abcam, ab3927), and cyclin E2 (Abcam, ab40890) were used to probe for the protein on the membrane. The detection was done by using HRP-conjugated antibodies (Santa Cruz) and ECL or ECL Plus reagents (Amersham Biosciences). Reactive proteins were identified with autoradiography.
TGF-β2 neutralization and Smad phosphorylation assays
Cells were plated in 96-well plates at a density of 5,000 cells per well and changed to fresh media with either 5 ng/ml of recombinant human (rh) TGF-β2 (R&D Systems, 302-B2) or BSA the next day. Cell-viability measurement was taken on the first day of TGF-β2 or BSA treatment and 3 days later by using WST-1 assay. To inhibit TGF-β2 action, cells were plated in 96-well plates at a density of 5,000 cells per well. After 24 hours, they were exposed to 10 μM SB431542 (Sigma-Aldrich, S4317) or DMSO (as vehicle control) before transfection with JMJD6 siRNA. The cells were changed to fresh media 48 hours after transfection, containing 10 μM SB431542 or DMSO. Cell viability was determined on the first day of SB431542 or DMSO treatment and 3 days later by WST-1 assay. For assessment of SMAD2 phosphorylation, cells were plated at approximately 50% confluence in six-well plates for 24 hours. The cells were pretreated for 2 hours with SB431542 (Sigma-Aldrich, S4317) or DMSO, before addition of 5 ng/ml of rhTGF-β2 (R&D Systems, 302-B2). Protein lysates were harvested 1 hour after rhTGF-β2 treatment for immunoblot analysis.
Clinical correlation between TGF-β2 and JMJD6
The super-cohort dataset was used to assess correlation, if any, between JMJD6 and TGF-β2 expression. TGF-β2 probesets, 209908_s_at, 220407_s_at, 209909_s_at, and 220406_at, were averaged for the clinical microarray data analysis. Correlation of JMJD6 expression and TGF-β2 expression was performed by using the Pearson correlation test on PASW Statistics 18 .
JMJD6 transcript levels correlate with poor prognosis in breast cancer
Hazard ratios of JMJD6 expression groups in various subtypes of breast cancer
JMJD6 expression in breast cancer subtypes
JMJD6 protein associates with high-grade and ER- tumors
JMJD6 increases proliferation in MCF-7 cells
JMJD6 enhances scattering and motility
JMJD6 expression inversely correlates with TGF-β2
JMJD6 possibly engages multiple pathways to increase cell proliferation
JMJD6 suppressed TGF-β2 expression and cell proliferation in both MCF-7 and MDA-MB 231 cells. However, TGF-β2 mediates cell-cycle arrest only in MCF-7 cells, but not in MDA-MB 231, T47D, and CAMA-1 cells [28–30]. Therefore, TGF-β2 may not be the mediator of cell-cycle arrest in the latter three cell lines, even though MDA-MB231s are responsive to TGF-β in terms of SMAD phosphorylation and TGF-β-mediated transcriptional changes . To test the functionality of TGF- β2, we did the following: (a) assessed Smad2/3 phosphorylation levels in both cells, (b) neutralized TGF-β2 by using a TGF-β type I receptor inhibitor SB431542 and assayed Smad phosphorylation and cell proliferation in the absence of JMJD6, and (c) treated MCF-7-J1OE cells with recombinant TGF- β2.
Last, treatment of MCF-7 J1-OE cells with recombinant TGF-β2 repressed proliferation in both Vec and J1-OE cells, suggesting that MCF-7 retained sensitivity to TGF-β2-mediated growth regulation despite increased JMJD6 levels (Figure 9C). Therefore, JMJD6 did not confer unresponsiveness to this growth factor, but probably mediated its effect via repression of gene expression. Together these data suggest that in MCF-7 cells, JMJD6 mediates cell-cycle regulation, in part by suppressing TGF-β2.
Clinical data for JMJD6 and TGF-β2
Through microarray informatics, we identified JMJD6 as a candidate oncogene associated with poor patient prognosis. Consistent with its potential as a marker of breast cancer aggressiveness, JMJD6 was expressed at highest levels in ER-, basal, claudin-low, HER2-enriched, and Luminal B tumor subtypes, which are known to be clinically associated with poor patient outcomes. Most important, in the less-aggressive ER+ subtypes (for example, Luminal A), high levels of JMJD6 could predict poor outcome and possibly resistance to tamoxifen monotherapy. Protein analysis by using tissue microarray confirmed that high JMJD6 expression is consistently associated with ER- disease, higher grade, and advanced stage. These data demonstrate for the first time that JMJD6 is a relevant prognostic biomarker in breast cancer.
By phenotypic and functional analysis, we found that JMJD6 induced an increase in cell scattering and increased the rate of wound closure in MCF-7 cells, but did not confer an invasive phenotype. In invasive cells like MDA-MB231 and BT-549 with high expression of JMJD6, siRNA-mediated suppression led to loss of both motility and invasiveness properties. Because forced JMJD6 expression did not confer invasiveness, this apparent loss of invasiveness most likely follows a loss in motility. Nonetheless, JMJD6 may have a critical role in epithelial cell movement, and we showed that this property is not restricted to endothelial cells . However, this appears to be a minor function of JMJD6, because its exogenous expression did not induce epithelial-to-mesenchymal transition (EMT) (that is, we did not observe a loss or gain in E-cadherin or vimentin expression, respectively, in MCF-7 J1-OE cells).
The most prominent effect of JMJD6 perturbation was on cell proliferation. SiRNA-mediated attenuation of JMJD6 in multiple breast cancer cells led to a decrease in cell proliferation without activation of cellular apoptosis, whereas forced expression in MCF-7 resulted in a massive increase in cell proliferation. This finding is consistent with the observation that JMJD6-knockout mice are small and show growth retardation . The role of JMJD6 in proliferation is further substantiated by our microarray analysis, which revealed that modulation of JMJD6 expression significantly affected the expression levels of a number of cell cycle-associated genes (see Additional file 10, Table S4). Although JMJD6 is thought to mediate splicing by physical interaction with U2AF65, we obtained very little evidence for alternate transcripts in both cell lines. Conversely, we documented a large number of transcriptional changes in J1-OE clones and JMJD6 knockdowns.
The TGF-β pathway, particularly TGF-β2, was downregulated when JMJD6 was overexpressed and induced when JMJD6 was depleted. We validated the inverse relation between JMJD6 and TGF-β2 at both RNA and protein levels in these cellular systems. We extended this observation to clinical samples and observed an inverse correlation between JMJD6 and TGF-β2 in our breast cancer cohorts. Such antagonistic roles of JMJD6 and TGF-β2 have a precedent in eye development. One of the distinctive developmental defects of JMJD6-knockout mice is the thinning of the retinal layer . Coincidentally, the knockout of TGF-β2 results in the hyperplasia of the neuroblastic layer of the retina . These data suggest that JMJD6 and TGF-β2 may be functionally linked in cell-cycle regulation and in development.
Canonically, TGF-βs are known to exert antiproliferative effects by upregulating cyclin-dependent kinase inhibitors, p15 and p21, and/or downregulation of CDK2 and cyclin E activity [26, 27, 33–35]. In both MCF-7 and MDA-MB 231 transfected with JMJD6 siRNA, we observed suppression of cyclin E expression, and an increase in cyclin E was evident when JMJD6 was overexpressed in MCF-7 cells. Therefore, in both cell lines, JMJD6 may exert a proliferative effect through a direct increase in cyclin E protein levels, or this increase may be a consequence of JMJD6-mediated suppression of TGF-β2. In both MCF-7 and MDA-MB231, the downstream effectors, Smads, were phosphorylated on JMJD6 siRNA-mediated secretion of TGF-β2. Specifically, in MCF-7, inhibition of TGF-β activity by using a TGF-β type I receptor (Alk5) inhibitor resulted in the loss of Smad phosphorylation, rescue of arrested cells, and continuation of proliferation (Figure 9). The Alk5 inhibitor did not reverse cell-cycle arrest in MDA-MB 231 cells because they are refractory to the antiproliferative effect of TGF-β, suggesting that the JMJD6-cyclin E axis may function independent of TGF-β2 in these cells. Intriguingly, cyclin E is associated with poor prognosis, chromosomal instability, and trastuzumab resistance, suggesting that the long-term dysregulation of cell-cycle mediators by JMJD6 may affect more than just proliferation [36–38].
Our initial microarray analysis selected genes that were commonly regulated by JMJD6 in both MCF-7 and MDA-MB 231 cells. To elucidate further the mechanisms behind JMJD6 siRNA-mediated growth suppression in MDA-MB 231 cells, we reanalyzed gene-expression changes unique to MDA-MB 231 cells alone. We found 1,864 probesets, with significant enrichment of genes involved in cellular death, growth and proliferation, and cell movement (P < 0.01; see Additional file 12, Figure S8). Close inspection showed at least 28 individual genes in this proliferation gene cassette (see Additional file 13, Table S5); however, no connectivity or compelling pathway emerged that could be investigated further.
In summary, our data indicate that JMJD6 has conserved functions and often affects similar pathways in a congruent manner across multiple cell types and at a gene-expression and phenotypic level. JMJD6 has ability to promote cancer cell proliferation and motility, which in turn may augment cancer virulence in vivo. In the clinic, JMJD6 associates with advanced grade, an aggressive phenotype, and serves as a marker of poor prognosis in breast cancer. We propose that JMJD6 staining (with IHC) may serve a dual purpose in the clinic: to predict poor outcome in patients, particularly in the ER+ subtype, and to identify a patient subgroup wherein specific inhibitors of JMJD6 may facilitate the pathologic downstaging of tumors in the neoadjuvant setting.
Dulbecco Modified Eagle Medium
distant metastasis-free survival
vascular endothelial growth factor receptor 1
human epidermal growth factor receptor 2
ingenuity pathway analysis
Jumonji domain-containing 6 protein
MCF-7 JMJD6 overexpression
real-time polymerase chain reaction
serine protease inhibitor Kazal type 1
transforming growth factor-β
U2 auxiliary factor 65.
This work was funded by the Agency for Science, Technology and Research (A*STAR) of Singapore. YFL is a recipient of the A*STAR Graduate Scholarship. We thank Keith Rogers, Susan Rogers, and Hassan Hall of the Histology Department for immunohistochemical staining, the Confocal and High Content Screening facility of Basement Shared Facilities (BSF), and the Agency of Science, Technology and Research (A*STAR) for their services. We thank Dr Paturu Kondaiah, Indian Institute of Science, Bangalore, India, for useful discussions.
- Soon WWML, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai K, Liu ET: Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med. 2011, 3: 451-464. 10.1002/emmm.201100150.View ArticleGoogle Scholar
- Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RAB, Henson PM: A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 2000, 405: 85-90. 10.1038/35011084.View ArticleGoogle Scholar
- Bose J, Gruber A, Helming L, Schiebe S, Wegener I, Hafner M, Beales M, Kontgen F, Lengeling A: The phosphatidylserine receptor has essential functions during embryogenesis but not in apoptotic cell removal. J Biol. 2004, 3: 15-10.1186/jbiol10.View ArticleGoogle Scholar
- Cui P, Qin B, Liu N, Pan G, Pei D: Nuclear localization of the phosphatidylserine receptor protein via multiple nuclear localization signals. Exp Cell Res. 2004, 293: 154-163. 10.1016/j.yexcr.2003.09.023.View ArticleGoogle Scholar
- Chang B, Chen Y, Zhao Y, Bruick RK: JMJD6 Is a histone arginine demethylase. Science. 2007, 318: 444-447. 10.1126/science.1145801.View ArticleGoogle Scholar
- Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, Kessler B, Nielsen ML, Schmitz C, Butler DS, Yates JR, Delahunty CM, Hahn P, Lengeling A, Mann M, Proudfoot NJ, Schofield CJ, Böttger A: Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science. 2009, 325: 90-93. 10.1126/science.1175865.View ArticleGoogle Scholar
- Boeckel J-N, Guarani V, Koyanagi M, Roexe T, Lengeling A, Schermuly RT, Gellert P, Braun T, Zeiher A, Dimmeler S: Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1. Proc Natl Acad Sci USA. 2011, 108: 3276-3281. 10.1073/pnas.1008098108.View ArticleGoogle Scholar
- Hong X, Zang J, White J, Wang C, Pan CH, Zhao R, Murphy RC, Dai S, Henson P, Kappler JW, Hagman J, Zhang G: Interaction of JMJD6 with single-stranded RNA. Proc Natl Acad Sci USA. 2010, 107: 14568-14572. 10.1073/pnas.1008832107.View ArticleGoogle Scholar
- Team RDC: R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2010Google Scholar
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80-10.1186/gb-2004-5-10-r80.View ArticleGoogle Scholar
- Li C, Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007, 8: 118-127. 10.1093/biostatistics/kxj037.View ArticleGoogle Scholar
- Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009, 27: 1160-1167. 10.1200/JCO.2008.18.1370.View ArticleGoogle Scholar
- UNC Microarray Database. [https://genome.unc.edu/pubsup/breastGEO]
- Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12: R68-10.1186/bcr2635.View ArticleGoogle Scholar
- SigmaPlot for Windows. 2008, Systat Software, Inc., San Jose, CA, 11.0
- Salto-Tellez M, Nga ME, Han HC, Wong AS, Lee CK, Anuar D, Ng SS, Ho M, Wee A, Chan YH, Soong R: Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer. 2007, 96: 776-782. 10.1038/sj.bjc.6603551.View ArticleGoogle Scholar
- Das K, Mohd Omar MF, Ong CW, Bin Abdul Rashid S, Peh BK, Putti TC, Tan PH, Chia KS, Teh M, Shah N, Soong R, Salto-Tellez M: TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. Pathology. 2008, 40: 441-449. 10.1080/00313020802198101.View ArticleGoogle Scholar
- PASW Statistics 18. 2009, Chicago: SPSS Inc., 18.0.0
- Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB: Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res. 2006, 66: 11370-11380. 10.1158/0008-5472.CAN-06-2106.View ArticleGoogle Scholar
- Ingenuity Systems. [http://www.ingenuity.com]
- Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863.View ArticleGoogle Scholar
- Eisen M: TreeView. 2002, 1.60Google Scholar
- Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8: R76-10.1186/gb-2007-8-5-r76.View ArticleGoogle Scholar
- Sørlie T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004, 40: 2667-2675. 10.1016/j.ejca.2004.08.021.View ArticleGoogle Scholar
- Moses HL: TGF-beta regulation of epithelial cell proliferation. Mol Reprod Dev. 1992, 32: 179-184. 10.1002/mrd.1080320215.View ArticleGoogle Scholar
- Robson CN, Gnanapragasam V, Byrne RL, Collins AT, Neal DE: Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol. 1999, 160: 257-266. 10.1677/joe.0.1600257.View ArticleGoogle Scholar
- Ravitz MJWC: Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res. 1997, 71: 165-207.View ArticleGoogle Scholar
- Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT: Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993, 92: 2569-2576. 10.1172/JCI116871.View ArticleGoogle Scholar
- Ji H, Stout LE, Zhang Q, Zhang R, Leung HT, Leung BS: Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1. J Cell Biochem. 1994, 54: 332-342. 10.1002/jcb.240540309.View ArticleGoogle Scholar
- Fanayan S, Firth SM, Butt AJ, Baxter RC: Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-β(TGF-β) and the type II TGF-β receptor. J Biol Chem. 2000, 275: 39146-39151. 10.1074/jbc.M006964200.View ArticleGoogle Scholar
- Chen CR, Kang Y, Massagué J: Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor β growth arrest program. Proc Natl Acad Sci USA. 2001, 98: 992-999. 10.1073/pnas.98.3.992.View ArticleGoogle Scholar
- Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T: TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development. 1997, 124: 2659-2670.Google Scholar
- Geng Y, Weinberg RA: Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA. 1993, 90: 10315-10319. 10.1073/pnas.90.21.10315.View ArticleGoogle Scholar
- Moustakas A, Pardali K, Gaal A, Heldin C-H: Mechanisms of TGF-[beta] signaling in regulation of cell growth and differentiation. Immunol Lett. 2002, 82: 85-91. 10.1016/S0165-2478(02)00023-8.View ArticleGoogle Scholar
- Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 1995, 92: 5545-5549. 10.1073/pnas.92.12.5545.View ArticleGoogle Scholar
- Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS: Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002, 347: 1566-1575. 10.1056/NEJMoa021153.View ArticleGoogle Scholar
- Spruck CH, Won K-A, Reed SI: Deregulated cyclin E induces chromosome instability. Nature. 1999, 401: 297-300. 10.1038/45836.View ArticleGoogle Scholar
- Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J: Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA. 2011, 108: 3761-3766. 10.1073/pnas.1014835108.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.